Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics

S Heres; M Lambert; R Vauth

doi:10.1016/S0924-9338(14)70001-X

Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics

Standard

Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. / Heres, S; Lambert, M; Vauth, R.

in: EUR PSYCHIAT, Jahrgang 29, Nr. Suppl 2, 01.11.2014, S. 1409-1413.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Heres, S, Lambert, M & Vauth, R 2014, 'Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics', EUR PSYCHIAT, Jg. 29, Nr. Suppl 2, S. 1409-1413. https://doi.org/10.1016/S0924-9338(14)70001-X

APA

Heres, S., Lambert, M., & Vauth, R. (2014). Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. EUR PSYCHIAT, 29(Suppl 2), 1409-1413. https://doi.org/10.1016/S0924-9338(14)70001-X

Vancouver

Heres S, Lambert M, Vauth R. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. EUR PSYCHIAT. 2014 Nov 1;29(Suppl 2):1409-1413. https://doi.org/10.1016/S0924-9338(14)70001-X

Bibtex

@article{0a480cf1a38a41dba96954008395e28f,

title = "Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics",

abstract = "The use of long-acting injectable antipsychotics (LAIs) in schizophrenia is usually restricted to patients in long-term treatment, who prefer them to oral antipsychotics, and to patients with multiple relapses who have a history of non-adherence. However, preliminary evidence from patients in the early phases of the disease suggest that second generation LAIs may be superior to second generation oral medications with regard to the control of negative symptoms and psychosocial functioning. Moreover, several studies have found that psychiatrists are generally reluctant to prescribe LAI antipsychotics and under-estimate their acceptability by patients. Key elements to take into account when offering a LAI in the early course of schizophrenia should include their potential superiority in allowing early detection of non-adherence and in reducing the number of rehospitalisations and relapses.",

author = "S Heres and M Lambert and R Vauth",

year = "2014",

month = nov,

day = "1",

doi = "10.1016/S0924-9338(14)70001-X",

language = "English",

volume = "29",

pages = "1409--1413",

journal = "EUR PSYCHIAT",

issn = "0924-9338",

publisher = "Elsevier Masson",

number = "Suppl 2",

}

RIS

TY - JOUR

T1 - Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics

AU - Heres, S

AU - Lambert, M

AU - Vauth, R

PY - 2014/11/1

Y1 - 2014/11/1

N2 - The use of long-acting injectable antipsychotics (LAIs) in schizophrenia is usually restricted to patients in long-term treatment, who prefer them to oral antipsychotics, and to patients with multiple relapses who have a history of non-adherence. However, preliminary evidence from patients in the early phases of the disease suggest that second generation LAIs may be superior to second generation oral medications with regard to the control of negative symptoms and psychosocial functioning. Moreover, several studies have found that psychiatrists are generally reluctant to prescribe LAI antipsychotics and under-estimate their acceptability by patients. Key elements to take into account when offering a LAI in the early course of schizophrenia should include their potential superiority in allowing early detection of non-adherence and in reducing the number of rehospitalisations and relapses.

AB - The use of long-acting injectable antipsychotics (LAIs) in schizophrenia is usually restricted to patients in long-term treatment, who prefer them to oral antipsychotics, and to patients with multiple relapses who have a history of non-adherence. However, preliminary evidence from patients in the early phases of the disease suggest that second generation LAIs may be superior to second generation oral medications with regard to the control of negative symptoms and psychosocial functioning. Moreover, several studies have found that psychiatrists are generally reluctant to prescribe LAI antipsychotics and under-estimate their acceptability by patients. Key elements to take into account when offering a LAI in the early course of schizophrenia should include their potential superiority in allowing early detection of non-adherence and in reducing the number of rehospitalisations and relapses.

U2 - 10.1016/S0924-9338(14)70001-X

DO - 10.1016/S0924-9338(14)70001-X

M3 - SCORING: Journal article

C2 - 25455704

VL - 29

SP - 1409

EP - 1413

JO - EUR PSYCHIAT

JF - EUR PSYCHIAT

SN - 0924-9338

IS - Suppl 2

ER -